Introducing: Komen TV!

Komen TVHave you ever wondered what Susan G. Komen for the Cure and its more than 120 Affiliates across the country and around the globe work on when not gearing up for a Race for the Cure® event?

For the first time, we’re taking audiences behind the scenes and beyond the sound bites to show everyone the depth, breadth and reach of the world’s largest breast cancer organization!

Susan G. Komen for the Cure Television is a 20 minute monthly broadcast focused on the incredible people who utilize Komen resources and make an impact every day in almost every community across the U.S. and in more than 50 countries!

Each month, we will feature a new show that contains stories on how your dollars help Komen carry out its critical mission of saving lives and ending breast cancer forever. Komen TV shines a light on doctors, researchers, advocates, and the breast cancer patients benefiting from their work. In addition, Komen TV highlights fundraising successes across the Komen family, introduces you to valued corporate partners, and so much more!

You can watch April’s broadcast here, but please join us and watch our latest broadcast below!

YouTube Preview Image

About the author

Susan G. Komen has written 342 articles for Susan G. Komen® | Blog

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen and launched the global breast cancer movement. Today, Komen is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure®, we have invested more than $1.9 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world.

  • Susan sonley

    SGK rocks! What a great idea to let everyone know all the good things Komen does. I’m with you 150%! to finding the cures and helping women (and men) everywhere! Thank you SGK!

    • http://www.facebook.com/profile.php?id=100003406215645 Rossella

      As a 16 year old male, your chances of haivng breast cancer are as close to aero as makes no difference. Men do get breast cancer, but fewer than 1% of those diagnosed with breast cancer are male, and most men diagnosed with it are over 60 though through breast cancer support groups I have met a very few men with breast cancer in their 50s..80% of all people diagnosed with breastcancer are over 50. It’s rare in women under 40, fewer than 0.1% of women diagnosed are under 30, and it’s almost unheard of in under 25s.So you can see how unlikely it would be for a teenage male to have breast cancer.Most breast lumps in men are a condition called gynaecomastia, a button-like growth under the nipple and areola area that can be felt and is sometimes visible to the naked eye and occasionally it can be quite tender.This increase in the amount of breast tissue is not a tumour and occurs due to changes in hormone balances at times like adolescence your age in other words.If your talking about about lumps you can feel in both breasts, then it’s even less likely (if possible) to be anything sinister the chances of breast cancer occuring in the same spot/s in both breasts simultaneously are tiny for anyone, and in a teenager (let alone a male one) the case would make medical history.What you’re feeling is almost certainly completely normal; mention it to your doctor next time you have an appointment with him/her, so that s/he can reassure you. But stop worrying about breast cancer.

  • Susan Sonley

    Love Komen TV!! Great to see the awareness spreading around the world to developing countries, where the mortality rates are 99%. We need to give all women access to breast health care!

  • Costello

    Cancer can be fix with different method.

    • aaron white

      I’ve hear a little of this one other Dr.. I think he is a doc. A very special person to me,is a current survivor. I don’t speak with her at the moment!!! She is abought to have her reconstruction done rather soon,if not already. She pushed most people out of her life,atleast myself,abought a month ago. She says she wanted to be alone when she has her last surgery,besides her family that is coming down. We were dating so,to me,the reasons to push me away during such a scary,and pivotal moment in the prossess of having,and beating Breast Cancer down for at least now,but hopefully she won’t ever have a reacurance. I was with her for the last bit of radiation,and would have been by her side through the entire durration of her ordeal with the disease,of possible death. Anyway we no longer speak,for more then one reason. We are both to blame for our issues ,just wish I could atleast know how she is!!! If u could share with me the alternative treatments,I would greatly appreciate it. Ive just started to look into the info on breast cancer,today. Hopeing just to have more knowledge of BC,somethin I should have done months ago. Mabey I would have made different,better choices,if I had a better understanding of what she was going through!!!!!!!! Our relationship might not have ended compleatly. A friendship would be great,with her. Reading abought

    • aaron white

      Reply to my adwsdmf388@gmail.com Alternative methods of treatment of breast cancer,and just cancer,in general,please
      Thanks Aaron White.

  • http://www.facebook.com/profile.php?id=100003406194734 mohd

    Yes, it is. With stage IV breast caecnr the choice of chemotherapy treatment depends on the patient’s goal of treatment. If the goal of treatment is to reduce symptoms and improve quality of life, it may be more desirable to select a chemotherapy treatment with minimal side effects. On the other hand, if the goal of treatment is to attempt to cure the caecnr, treatment with more aggressive chemotherapy regimens is opted. Either way, all the new advanced drug therapies have recorded average survival rates of fewer than 24 months—so your mom sure had a passion for life! Here are some recent trial findings:ET (Ellenceae (epirubicin) and Taxotereae (docetaxel)): In a randomized clinical trial comparing ET to FEC (fluorouracil, epirubicin, and cyclophosphamide) as first-line therapy for stage IV breast caecnr, the response rate to ET was 63%, compared to 31% for FEC. The average time to caecnr progression was 8.6 months for patients treated with ET, compared to 6.1 months for patients treated with FEC.TAC (docetaxel, doxorubicin, and cyclophosphamide): In an attempt to further improve treatment, a third drug has been added to the combination of doxorubicin and docetaxel and evaluated as initial treatment for patients with stage IV breast caecnr. Two years following treatment, nearly 60% of patients were still alive. The average survival had not yet been established past two years following treatment.AT (doxorubicin and paclitaxel): A recent clinical trial evaluated the use of AT in patients with stage IV breast caecnr. Patients received AT or a common chemotherapy combination consisting of fluorouracil, doxorubicin and cyclophosphamide (FAC). The results of the two groups were then directly compared. The average survival time was 23.3 months for patients receiving AT versus 18.3 months for patients receiving FAC.Taxotereae (docetaxel) and Xelodaae (capecitabine): Researchers conducted a clinical trial to directly compare docetaxel plus capecitabine to docetaxel alone in the treatment of patients with stage IV breast caecnr. Patients who received treatment with docetaxel/capecitabine were more likely to experience anti-caecnr responses, have a longer time to caecnr progression and survive longer when compared to patients treated with docetaxel alone. One year following therapy, 57% of patients treated with docetaxel/capecitabine had survived, compared to only 47% of patients treated with docetaxel alone.Gemzarae (gemcitabine): Recently, clinical trials indicated that gemcitabine and paclitaxel is an effective treatment option for initial therapy of stage IV breast caecnr. In one trial, researchers from France treated 36 patients with stage IV breast caecnr or locally advanced breast caecnr with gemcitabine and paclitaxel. Following therapy, approximately 42% of patients had an anti-caecnr response. The average time to caecnr progression was approximately 7.5 months.